Compare Prudential Financial Inc (PRU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Prudential Financial Inc trades at $114.08 (market cap $38.76B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Prudential Financial Inc pays the higher dividend (4.98%). Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PRU | REGN | |
|---|---|---|
Market Cap | $38.76B | $76.40B |
Volume | 1,604,078 | 626,381 |
Sector | Financials | Health |
52-Week High | $125.13 | $852.03 |
52-Week Low | $92.00 | $557.73 |
Typical Hold Time | 145 Days | 107 Days |
Enterprise Value | $67.54B | $71.12B |
Dividend Yield | 4.98% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.53, down slightly by 0.01%. The stock exhibits a bearish technical trend with key support at $110, while fundamentals show a P/E of 10.19 and net income margin of 6.04%. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a strategic $3 billion capital rotation and $750 million cost savings plan (MarketBeat, 2026-09-17).
The outlook is mixed: valuation appears attractive with low P/E and P/S ratios, and higher interest rates may boost investment income. However, analyst consensus is cautious with a $105.67 price target below current levels, and technical indicators signal bearish pressure. Risks include execution of strategic initiatives and macroeconomic sensitivity.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
